Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 17/20 | 0.66 |
| ▸ | PDE4B | Q07343 | 17/20 | 0.66 |
| ▸ | PDE4A | P27815 | 4/20 | 0.66 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889923 | 0.90 | PDE4D (0.74) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL30084849 | 0.90 | PDE4D (0.74) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL7371319 | 0.86 | PDE4D (0.80) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL30084836 | 0.86 | PDE4D (0.80) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL30084831 | 0.86 | PDE4D (0.80) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL7534706 | 0.86 | PDE4D (0.80) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL2889353 | 0.85 | PDE4D (0.68) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL28899604 | 0.85 | PDE4D (0.68) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL29824400 | 0.85 | PDE4D (0.68) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL2908650 | 0.84 | PDE4D (0.81) | PDE4DPDE4BPDE4APDE4CCYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522612-B2 | PDE4 inhibitors, pharmaceutical compositions, and therapeutic applications | BIOTHERYX INC. (US) | 2026-01-13 | — | — | US | disclosed |
| CN-117203196-A | PDE4 degrading agents, pharmaceutical compositions and therapeutic applications | 拜欧斯瑞克斯公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4259621-A1 | PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | Biotheryx, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230071529-A1 | PDE4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-03-09 | — | — | US | disclosed |
| EP-4073074-A1 | PDE4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | Biotheryx, Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| WO-2022132603-A1 | PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2021119571-A1 | PDE4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| CN-103613533-A | Preparation method of roflumilast related substance D | JIANGSU AVENTIS PHARMACEUTICAL CO LTD | 2014-03-05 | — | — | CN | disclosed |
| CN-102964297-A | Preparation method and detection method of roflumilast material | GUIZHOU XINBANG PHARMACEUTICAL CO LTD | 2013-03-13 | — | — | CN | disclosed |
| WO-2012155812-A1 | PROCESSES FOR THE PREPARATION OF ROFLUMILAST AND INTERMEDIATES THEREOF | 上海特化医药科技有限公司 (CN) | 2012-11-22 | — | — | WO | disclosed |
| US-20120052122-A1 | Treatment Of Chronic Obstructive Pulmonary Disease With Phosphodiesterase-4 Inhibitor | NYCOMED GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230071529-A1 | PDE4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | PDE4A, PDE4B, PDE2A | PDE4D 9/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20120052122-A1 | Treatment Of Chronic Obstructive Pulmonary Disease With Phosphodiesterase-4 Inhibitor | PDE4A, PDE3B, PDE4B | PDE4D 7/4885PDE4B 3/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.